{"id":204340,"date":"2010-01-20T15:40:13","date_gmt":"2010-01-20T20:40:13","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=59338"},"modified":"2010-01-20T15:40:13","modified_gmt":"2010-01-20T20:40:13","slug":"amag-pharma-to-sell-3m-shares","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/204340","title":{"rendered":"Amag Pharma to Sell 3M Shares"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/kidney-disease\/\">Kidney Disease<\/a><\/div>\n<p>\t\t<strong>Ryan McBride wrote:<\/strong><\/p>\n<p>Amag Pharmaceuticals (NASDAQ:<a href=\"http:\/\/finance.yahoo.com\/q?s=AMAG\">AMAG<\/a>), a Lexington, MA-based firm with a lead product for patients with chronic kidney disease, <a href=\"http:\/\/www.snl.com\/irweblinkx\/file.aspx?IID=4166432&amp;FID=8875311\">announced<\/a> yesterday that it plans to sell 3 million shares of common stock in a public offering. Additionally, the firm is allocating 450,000 shares for underwriters to cover potential over-allotments. The company&#8217;s stock traded at $49.03 per share at 3:23 pm ET today.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/01\/20\/amag-pharma-to-sell-3m-shares\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Amag%20Pharma%20to%20Sell%203M%20Shares%20http:\/\/xconomy.com\/?p=59338\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/01\/20\/amag-pharma-to-sell-3m-shares\/&#038;t=Amag%20Pharma%20to%20Sell%203M%20Shares\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/01\/20\/amag-pharma-to-sell-3m-shares\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Amag+Pharma+to+Sell+3M+Shares&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F01%2F20%2Famag-pharma-to-sell-3m-shares%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=8922534a1c7c2b6c0d163d84d5a57b9c&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=8922534a1c7c2b6c0d163d84d5a57b9c&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/ozenYuLh7DXniwihG--8CtUPQHM\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/ozenYuLh7DXniwihG--8CtUPQHM\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/ozenYuLh7DXniwihG--8CtUPQHM\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/ozenYuLh7DXniwihG--8CtUPQHM\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/t_JNe7wu0jU\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Life Sciences, deals, Kidney Disease Ryan McBride wrote: Amag Pharmaceuticals (NASDAQ:AMAG), a Lexington, MA-based firm with a lead product for patients with chronic kidney disease, announced yesterday that it plans to sell 3 million shares of common stock in a public offering. Additionally, the firm is allocating 450,000 shares for underwriters to cover potential over-allotments. [&hellip;]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-204340","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/204340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=204340"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/204340\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=204340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=204340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=204340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}